The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
Abstract
Objective: Endocrine immune-related adverse events (endocrinopathies) are increasingly prevalent with the use of immune checkpoint inhibitors for the treatment of metastatic melanoma and other malignancies. There are no evidence-based guidelines for the screening or management of such patients. To describe the spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors. Design: A prospective study conducted at Melanoma Institute Australia between April 2014 and October 2015. Methods: A total of 177 patients were treated with (a) ipilimumab (n = 15), (b) anti-PD-1 (nivolumab, pembrolizumab) (n = 103) or (c) combination ipilimumab and anti-PD-1 (n = 59) and were screened and managed for the subsequent endocrinopathies. The main outcome measures were the incidence and kinetics of endocrinopathy by immunotherapy drug class. Results: Thirty-one patients (18%) developed an endocrine immune-related adverse event (thyroid dysfunction: 14%, hypophysitis: 6% and autoimmune diabetes: 0.6%). Combination immunotherapy was more likely to result in a single or multiple endocrinopathy compared to anti-PD-1 monotherapy (27% vs 9% and 7% vs 0% respectively,P < 0.01). Endocrinopathies occurred after a median of 8 weeks from treatment commencement (range: 12–225 days), with combination immunotherapy resulting in significantly earlier onset compared to ipilimumab (median: 30 vs 76 days,P = 0.046). The majority of endocrinopathies were identified in asymptomatic patients with hormonal screening. There were no baseline predictors for endocrinopathy. Conclusions: Combination immunotherapy has a greater risk of development of endocrinopathy compared to anti-PD-1 monotherapy. Regular biochemical profiling of patients, particularly within the first twelve weeks, results in early detection of endocrinopathy to minimise morbidity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is still unclear if steroid-sparing regimens decrease the risk of PTDM with studies showing mixed results.1591–1595”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1592]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Self-citation
Research works printed but not linked: 28
- Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort., Presented at the 2016 Annual Meeting of the American Society of Clinical Oncology
- 2014, Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis, Clinical Neurology and Neurosurgery, 125, 125, 10.1016/j.clineuro.2014.06.011 · DOI
- 2015, Immune checkpoint blockade in cancer therapy, Journal of Clinical Oncology, 33, 1974, 10.1200/JCO.2014.59.4358 · DOI · Paper page
- 2010, Improved survival with Ipilimumab in patients with metastatic melanoma, New England Journal of Medicine, 363, 711, 10.1056/NEJMoa1003466 · DOI · Paper page
- 2012, Management of immune-related adverse events and kinetics of response with ipilimumab, Journal of Clinical Oncology, 30, 2691, 10.1200/JCO.2012.41.6750 · DOI · Paper page
- 2016, Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review, Clinical Endocrinology, 85, 331, 10.1111/cen.13063 · DOI · Paper page
- 2010, The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications., Seminars in Oncology, 37, 499, 10.1053/j.seminoncol.2010.09.007 · DOI · Paper page
- 2015, Pembrolizumab versus Ipilimumab in advanced melanoma, New England Journal of Medicine, 372, 2521, 10.1056/NEJMoa1503093 · DOI · Paper page
- 2016, Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights, Pituitary, 19, 82, 10.1007/s11102-015-0671-4 · DOI · Paper page
- 2015, Nivolumab in previously untreated melanoma without BRAF mutation, New England Journal of Medicine, 372, 320, 10.1056/NEJMoa1412082 · DOI · Paper page
- 2017, Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature., Targeted Oncology, 12, 235, 10.1007/s11523-017-0480-y · DOI
- 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune check point antibodies, Annals of Oncology, 26, 2375, 10.1093/annonc/mdv383 · DOI · Paper page
- 2014, Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution, Endocrine-Related Cancer, 21, 371, 10.1530/ERC-13-0499 · DOI · Paper page
- 2013, Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma, Cancer, 119, 1675, 10.1002/cncr.27969 · DOI · Paper page
- 2012, Hypophysitis induced by monoclonal antibodies to Cytotoxic T Lymphocyte Antigen 4: challenges from a new cause of a rare disease, Oncologist, 17, 525, 10.1634/theoncologist.2011-0404 · DOI
- 2015, Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy, Diabetes Care, 38, 55, 10.2337/dc14-2349 · DOI · Paper page
- 2015, Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma, New England Journal of Medicine, 372, 2006, 10.1056/NEJMoa1414428 · DOI · Paper page
- 2014, Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma, Journal of Clinical Endocrinology and Metabolism, 99, 4078, 10.1210/jc.2014-2306 · DOI · Paper page
- 2013, Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy, Experimental and Clinical Endocrinology and Diabetes, 121, 581, 10.1055/s-0033-1355337 · DOI
- 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Current Opinion in Immunology, 24, 207, 10.1016/j.coi.2011.12.009 · DOI · Paper page
- 2016, Low level autoantibodies can be frequently detected in the general Australian population, Pathology, 48, 483, 10.1016/j.pathol.2016.03.014 · DOI
- 2017, Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma., Journal of Clinical Oncology, 35, 785, 10.1200/JCO.2015.66.1389 · DOI · Paper page
- 2015, Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma, New England Journal of Medicine, 373, 23, 10.1056/NEJMoa1504030 · DOI · Paper page
- 2013, Endocrine side effects induced by immune checkpoint inhibitors, Journal of Clinical Endocrinology and Metabolism, 98, 1361, 10.1210/jc.2012-4075 · DOI · Paper page
- 2014, Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study, Cancer Research, 21, 749
- 2016, Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treatment Reviews, 45, 7, 10.1016/j.ctrv.2016.02.003 · DOI · Paper page
- 2015, Long term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anto-CTLA-4 antibody in melanoma, European Journal of Endocrinology, 172, 195, 10.1530/EJE-14-0845 · DOI · Paper page
- 2012, Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review., European Journal of Endocrinology, 167, 1, 10.1530/EJE-12-0167 · DOI
Cited by
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
de Filette, J. M. K., Pen, J. J., Decoster, L., Vissers, T., Bravenboer, B., Van der Auwera, B. J., Gorus, F. K., Roep, B. O., Aspeslagh, S., Neyns, B., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0291 · Cited by 275
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
Beaubier, N., Tell, R., Lau, D., Parsons, J. R., Bush, S., Perera, J., Sorrells, S., Baker, T., Chang, A., Michuda, J., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26797 · Cited by 244
Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus
Clotman, K., Janssens, K., Specenier, P., Weets, I., & De Block, C. E. M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00728 · Cited by 232
Metadata
- Authors
- Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Tsang, Venessa H
- ORCID
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02
- Volume
- 178
- Issue
- 2
- Pages
- 173-180
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2769908638
- Cited by
- 142
- References
- 30
- Citations by year
- 2025: 9 · 2024: 12 · 2023: 17 · 2022: 19 · 2021: 23 · 2020: 25 · 2019: 22 · 2018: 15
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- endocrine disorders, immune-related adverse events, immune checkpoint inhibitors, metastatic melanoma, ipilimumab, anti-PD-1 therapy, nivolumab, pembrolizumab, combination immunotherapy, thyroid dysfunction, hypophysitis, autoimmune diabetes
- MeSH terms
- Hypophysitis, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Australia, Autoimmune Diseases, Diabetes Mellitus, Drug Therapy, Combination, Endocrine System Diseases, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Prospective Studies, Thyroid Diseases, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. https://app.cochat.ai/papers/10.1530/eje-17-0810
- The paper
- Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018). The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. European Journal of Endocrinology. https://doi.org/10.1530/eje-17-0810
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.